Sera Prognostics (NASDAQ:SERA) Trading Up 0.4%

Sera Prognostics, Inc. (NASDAQ:SERA) rose 0.4% during mid-day trading on Friday . The stock traded as high as $7.35 and last traded at $7.25. Approximately 49,759 shares changed hands during trading, a decline of 75% from the average daily volume of 196,666 shares. The stock had previously closed at $7.22.

Sera Prognostics Trading Up 0.4 %

The stock’s fifty day simple moving average is $7.12 and its 200 day simple moving average is $8.33. The company has a market cap of $241.93 million, a price-to-earnings ratio of -6.78 and a beta of 1.03.

Sera Prognostics (NASDAQ:SERA) last posted its quarterly earnings results on Wednesday, August 7th. The company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.02). The company had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.08 million. Sera Prognostics had a negative net margin of 11,843.79% and a negative return on equity of 46.71%. During the same period in the prior year, the business posted ($0.34) EPS. On average, analysts predict that Sera Prognostics, Inc. will post -0.95 EPS for the current year.

Insider Transactions at Sera Prognostics

In related news, insider John J. Boniface sold 5,022 shares of the company’s stock in a transaction dated Wednesday, August 7th. The shares were sold at an average price of $7.42, for a total value of $37,263.24. Following the completion of the sale, the insider now owns 129,847 shares of the company’s stock, valued at $963,464.74. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, insider John J. Boniface sold 5,022 shares of the stock in a transaction that occurred on Wednesday, August 7th. The stock was sold at an average price of $7.42, for a total value of $37,263.24. Following the completion of the transaction, the insider now directly owns 129,847 shares in the company, valued at $963,464.74. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Zhenya Lindgardt sold 26,867 shares of Sera Prognostics stock in a transaction on Monday, June 10th. The shares were sold at an average price of $8.11, for a total value of $217,891.37. Following the completion of the sale, the chief executive officer now owns 869,245 shares in the company, valued at approximately $7,049,576.95. The disclosure for this sale can be found here. Insiders have sold a total of 56,492 shares of company stock worth $441,445 in the last quarter. Company insiders own 15.80% of the company’s stock.

Institutional Trading of Sera Prognostics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Sanders Morris Harris LLC acquired a new position in Sera Prognostics during the 1st quarter worth about $174,000. StepStone Group LP acquired a new stake in shares of Sera Prognostics during the fourth quarter worth about $61,000. The Manufacturers Life Insurance Company acquired a new stake in shares of Sera Prognostics during the second quarter worth about $68,000. Renaissance Technologies LLC purchased a new position in shares of Sera Prognostics in the second quarter valued at approximately $162,000. Finally, American Century Companies Inc. grew its holdings in shares of Sera Prognostics by 12.7% in the second quarter. American Century Companies Inc. now owns 25,682 shares of the company’s stock valued at $152,000 after purchasing an additional 2,891 shares in the last quarter. Hedge funds and other institutional investors own 54.64% of the company’s stock.

Sera Prognostics Company Profile

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.